Recent years have seen a surge in innovation in drug delivery, particularly for chronic conditions, where rising healthcare costs exacerbate the challenge of managing already expensive-to-treat conditions.
U.S. Rep. David Schweikert called for making GLP-1s more widely accessible, claiming this will help more people lose weight and, in turn, take pressure off healthcare costs in the U.S.
Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a 'promising new therapy' for patients with Crohn's disease.